Prognostic significance of KRAS mutations. (A) Prognostic significance of KRAS mutations in pediatric patients with MLL-r AML who were in the TARGET and AML-05 cohorts (n = 160). (B) Prognostic significance of KRAS mutations in pediatric patients with non–MLL-r AML enrolled in the TARGET cohort (n = 581). (C) Prognostic significance of KRAS mutations in adult patients with MLL-r AML in the MLL laboratory (n = 81). The log-rank test was used for survival estimates.